Results 141 to 150 of about 3,851,506 (357)

Evidence for a regulatory idiotypic network in the in vivo response to H-2 antigens. [PDF]

open access: yes, 1985
Treatment of BALB/c mice with purified pig antiidiotype to 11-4.1 (anti-H-2Kk) monoclonal antibody has been found previously to induce the appearance of idiotype-bearing molecules (Id') in the serum of these mice, in the absence of detectable antigen ...
Bluestone, JA, Rabinowitz, R, Sachs, DH
core  

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

open access: yesMolecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak   +10 more
wiley   +1 more source

Detection of Bovine Respiratory Syncytial Virus in Cattle: A Systematic Review and Meta-Analysis

open access: yesRuminants
Bovine respiratory syncytial virus (BRSV) is an economically important pathogen of cattle and contributes to the bovine respiratory disease complex (BRDC).
Gebremeskel Mamu Werid   +6 more
doaj   +1 more source

“Detection of SV40 like viral DNA and viral antigens in malignant pleural mesothelioma.” M. Ramael, J. Nagels, H. Heylen, S. De Schepper, J. Paulussen, M. De Maeyer and C. Van Haesendonck.Eur Respir J1999; 14: 1381–1386. [PDF]

open access: bronze, 2020
M Ramael   +31 more
openalex   +1 more source

Revisiting Mission‐Oriented Cancer Research to tackle the increasing burden of cancer in Europe–a policy perspective

open access: yesMolecular Oncology, EarlyView.
Translational cancer research and its implementation through competitively selected Comprehensive Cancer Centers across Europe should be the primary policy focus for addressing the increasing cancer burden in Europe and counteract the present main strategy to convert cancer to a chronic disease.
Manuel Heitor   +2 more
wiley   +1 more source

Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells [PDF]

open access: yes, 2001
The inducible costimulator receptor (ICOS) is a third member of the CD28 receptor family that regulates T cell activation and function. ICOS binds to a newly identified ligand on antigen presenting cells different from the CD152 ligands CD80 and CD86. We
Aicher, A   +9 more
core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Antigen‐specific polyfunctional cytotoxic T cells differentiate intraocular from peripheral blood immune responses in posterior uveitis

open access: yesClinical & Translational Immunology
Objectives Peripheral blood is frequently used to study the immune response in human uveitis because of the inaccessibility of ocular tissue samples. To determine whether peripheral blood immune cells accurately reflect the intraocular immune response ...
Kaiser Alam   +6 more
doaj   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

open access: yesMolecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

Home - About - Disclaimer - Privacy